Microdosing Psychedelics to Improve Mood

Summary

This trial aims to examine the safety and efficacy of small (2mg) sub-hallucinogenic doses of psilocybin in people with Major Depressive Disorder.

Timeline

Start

2023-07-15

Primary completion

2024-12-21

Completion

2025-02-01

Publications

• Beidas Z, Ragnhildstveit A, Blackman A, Anderson T, Fewster E, Syed OA, Sobolenko V, Kanca IK, Jaglinska M, Son T, Farb N, Petranker R. Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial. BJPsych Open. 2026 Feb 16;12(2):e65. doi: 10.1192/bjo.2025.10968.

Drugs

Indications